Moberg Pharma AB (publ) Cash Flow Conversion Efficiency
Moberg Pharma AB (publ) cash flow conversion efficiency. Based on the latest financial reports, Moberg Pharma AB (publ) (MOB) has a cash flow conversion efficiency ratio of 0.002x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr1.52 Million ≈ $163.36K USD) by net assets (Skr665.22 Million ≈ $71.59 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Moberg Pharma AB (publ) (2008–2025)
Cash flow conversion efficiency of Moberg Pharma AB (publ) from 2008 to 2025. This chart illustrates how Moberg Pharma AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Moberg Pharma AB (publ) stock price today for real-time trading data and today's change.
Moberg Pharma AB (publ) Cash Flow Conversion Ratio Explained
Moberg Pharma AB (publ) cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Moberg Pharma AB (publ) Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Moberg Pharma AB (publ) ranked by their cash flow conversion efficiency. Also see MOB company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Marpai Inc
NASDAQ:MRAI
|
0.014x |
|
TECO Image Systems Co Ltd
TWO:5438
|
-0.017x |
|
Titania Holding AB Series B
ST:TITA-B
|
-0.030x |
|
W S Industries (I) Limited
NSE:WSI
|
0.030x |
|
POBIS TNC CO. Ltd
KQ:016670
|
0.095x |
|
New Hoong Fatt Holdings Bhd
KLSE:7060
|
0.021x |
|
Global View Co Ltd
TW:3040
|
-0.005x |
|
Global Self Storage Inc
NASDAQ:SELF
|
0.026x |
Annual Cash Flow Conversion Efficiency for Moberg Pharma AB (publ) (2008–2025)
The table below shows the annual cash flow conversion efficiency of Moberg Pharma AB (publ) from 2008 to 2025. Review free cash flow generation of Moberg Pharma AB (publ) to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr665.22 Million ≈ $71.59 Million |
Skr-17.49 Million ≈ $-1.88 Million |
-0.026x | -9.63% |
| 2024-12-31 | Skr686.82 Million ≈ $73.91 Million |
Skr-16.47 Million ≈ $-1.77 Million |
-0.024x | +55.89% |
| 2023-12-31 | Skr610.73 Million ≈ $65.72 Million |
Skr-33.20 Million ≈ $-3.57 Million |
-0.054x | -72.25% |
| 2022-12-31 | Skr533.58 Million ≈ $57.42 Million |
Skr-16.84 Million ≈ $-1.81 Million |
-0.032x | +10.43% |
| 2021-12-31 | Skr434.05 Million ≈ $46.71 Million |
Skr-15.30 Million ≈ $-1.65 Million |
-0.035x | +53.42% |
| 2020-12-31 | Skr395.58 Million ≈ $42.57 Million |
Skr-29.93 Million ≈ $-3.22 Million |
-0.076x | -302.29% |
| 2019-12-31 | Skr105.68 Million ≈ $11.37 Million |
Skr3.95 Million ≈ $425.30K |
0.037x | -69.94% |
| 2018-12-31 | Skr594.02 Million ≈ $63.93 Million |
Skr73.89 Million ≈ $7.95 Million |
0.124x | +27.68% |
| 2017-12-31 | Skr552.41 Million ≈ $59.45 Million |
Skr53.82 Million ≈ $5.79 Million |
0.097x | +404.98% |
| 2016-12-31 | Skr561.62 Million ≈ $60.44 Million |
Skr-17.94 Million ≈ $-1.93 Million |
-0.032x | -136.69% |
| 2015-12-31 | Skr352.82 Million ≈ $37.97 Million |
Skr30.72 Million ≈ $3.31 Million |
0.087x | +63.63% |
| 2014-12-31 | Skr303.75 Million ≈ $32.69 Million |
Skr16.16 Million ≈ $1.74 Million |
0.053x | +440.35% |
| 2013-12-31 | Skr201.49 Million ≈ $21.68 Million |
Skr-3.15 Million ≈ $-338.99K |
-0.016x | -129.40% |
| 2012-12-31 | Skr178.23 Million ≈ $19.18 Million |
Skr9.48 Million ≈ $1.02 Million |
0.053x | +145.26% |
| 2011-12-31 | Skr76.79 Million ≈ $8.26 Million |
Skr-9.02 Million ≈ $-970.70K |
-0.117x | +99.73% |
| 2010-12-31 | Skr687.70K ≈ $74.01K |
Skr-30.41 Million ≈ $-3.27 Million |
-44.224x | -5189.34% |
| 2009-12-31 | Skr30.21 Million ≈ $3.25 Million |
Skr-25.26 Million ≈ $-2.72 Million |
-0.836x | +63.51% |
| 2008-12-31 | Skr15.23 Million ≈ $1.64 Million |
Skr-34.89 Million ≈ $-3.75 Million |
-2.291x | -- |
About Moberg Pharma AB (publ)
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It offers MOB-015 for the treatment of nail fungus under the Terclara brand. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is based in Bromma, Sweden.